Company profile · Sponsor
Astellas
Astellas Pharma GmbH
- Pipeline
- 22
- Drugs
- 0
- Patents
- 0
Quick answer
Astellas (E7560A6) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 22 pipeline programs, 0 drugs, and 0 patents to this profile..
Company facts
Pipeline (22)
Search pipeline →-
ASP8951, Sodium Chloride 0.9% Intravenous Infusion BP
Astellas
Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
1 trial -
ASP8951, Sodium Chloride 0.9% Intravenous Infusion BP
Astellas
Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
1 trial -
AT132
Astellas
X-linked Myotubular Myopathy (XLMTM)
1 trial -
Avacincaptad pegol, FLUORESCEIN
Astellas
geographic atrophy
1 trial -
Mirabegron
Astellas
Neurogenic detrusor overactivity (NDO)
1 trial -
Placebo for fezolinetant film-coated tablets 45 mg, fezolinetant
Astellas
Moderate to Severe Vasomotor Symptoms (VMS)
1 trial -
Vidaza 25 mg/ml powder for suspension for injection, Gilteritinib
Astellas
Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy
1 trial -
Vyloy 100 mg powder for concentrate for solution for infusion., OXALIPLATIN, FOLINIC ACID, KEYTRUDA 25 mg/mL concentrate for solution for infusion, CAPECITABINE, FLUOROURACIL, KEYTRUDA 25 mg/mL concentrate for solution for infusion., KEYTRUDA 25 mg/mL concentrate for solution for infusion., Vyloy 100 mg powder for concentrate for solution for infusion., KEYTRUDA 25 mg/mL concentrate for solution for infusion., Sodium chloride 0.9% intravenous infusion, ASP8951, CAPECITABINE, KEYTRUDA 25 mg/mL concentrate fo
Astellas
Gastroesophageal Junction Adenocarcinoma, Gastric Cancer, Gastric Adenocarcinoma
1 trial -
enfortumab vedotin, VINFLUNINE , DOCETAXEL , PACLITAXEL
Astellas
Locally advanced or metastatic urothelial cancer
1 trial -
ASP1570, ASP1570, KEYTRUDA 25 mg/mL concentrate for solution for infusion
Astellas
Advanced Solid Tumors
1 trial -
ASP2957
Astellas
X-linked myotubular myopathy
1 trial -
ASP5541, ABIRATERONE ACETATE, PREDNISOLONE, PREDNISONE
Astellas
Prostate Cancer
1 trial -
ASP8951, Calcium Folinate 10 mg/ml Injection, Oxaliplatin Hospira 5 mg/ml concentrate for solution for infusion, OPDIVO 10 mg/mL concentrate for solution for infusion., Fluorouracil 50mg/ml Injection., OPDIVO 10 mg/mL concentrate for solution for infusion., OPDIVO 10 mg/mL concentrate for solution for infusion.
Astellas
Advanced cancer of the stomach or the gastroesophageal junction
1 trial -
ASP8951, PACLITAXEL, GEMCITABINE
Astellas
First Line Treatment in Subjects with Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma.
1 trial -
Advagraf 0.5 mg prolonged-release hard capsules, Advagraf 1 mg prolonged-release hard capsules, Advagraf 1 mg prolonged-release hard capsules, Advagraf 5 mg prolonged-release hard capsules, Advagraf 1 mg prolonged-release hard capsules, Advagraf 0.5 mg prolonged-release hard capsules, Advagraf 0.5 mg prolonged-release hard capsules, Advagraf 1 mg prolonged-release hard capsules, Advagraf 0.5 mg prolonged-release hard capsules, Advagraf 1 mg prolonged-release hard capsules, Advagraf 0.5 mg prolonged-release
Astellas
Prophylaxis of primary liver, kidney, heart, lung, and intestinal organ transplant rejection
1 trial -
PREDNISONE , ABIRATERONE , MDV3100
Astellas
Prostate Cancer
1 trial -
Zarzio 30 MU/0.5 ml solution for injection or infusion in pre-filled syringe, Gilteritinib, ARA-cell® 40 mg Injektion 20 mg/ml Injektionslösung / Konzentrat zur Herstellung einer Infusionslösung, Gilteritinib, Bendarabin 50 mg Pulver zur Herstellung einer Injektions- oder Infusionslösung, Citarabina Hikma 1 g/10mL Soluzione Iniettabile
Astellas
FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
1 trial -
A Study to Learn How Enzalutamide, Apalutamide and Bicalutamide Affect the Way Fezolinetant is Processed by the Body in Men With Prostate Cancer
Astellas
Hot Flush
1 trial -
A study of ASP2138 given by itself or given with other cancer treatments in adults with stomach cancer, gastroesophageal junction cancer, or pancreatic cancer
Astellas
Gastroesophageal Junction (GEJ) Adenocarcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma
1 trial -
A study of ASP3082 in adults with advanced solid tumors
Astellas
Solid Tumor
1 trial -
A study of gilteritinib in adults with advanced ALK-positive non-small cell lung cancer (NSCLC)
Astellas
Locally advanced or metastatic NSCLC
1 trial -
A study to find a suitable dose of ASP5834 in adults with solid tumors
Astellas
Locally advanced (unresectable) or metastatic solid tumor malignancies who harbor a KRAS mutation (G12V, G12D, G12C, G12A, G12R or G13D mutation) or KRAS amplification
1 trial
Frequently asked questions
What is Astellas?
Astellas (E7560A6) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 22 pipeline programs, 0 drugs, and 0 patents to this profile..
What pipeline programs does Astellas sponsor?
We track 22 ClinicalTrials.gov-linked programs for Astellas, including ASP8951, Sodium Chloride 0.9% Intravenous Infusion BP and 21 more. Open each program for phase, modality, NCT IDs, and indication details.
Where does Astellas company data come from?
Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.